Participants 69 103 5
premenopausal breast cancer trial.
Participants 699 738 5
premenopausal women with breast cancer.
Participants 757 1028 9
Clinically established pathological parameters were assessed and related to the tamoxifen response in 500 available tumour specimens from 564 premenopausal patients with breast cancer randomised to either two years of tamoxifen or no treatment with 14 years of follow up.
Participants 1832 1891 5
future treatment decisions for patients with breast cancer.
